Next |
home / stock / vyne / vyne message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $VYNE 26% v1,5M c.226 f58,035M H.23 ML.11 lod.16 | znewcar1 | investorshangout | 01/06/2023 10:08:06 PM |
znewcar1: VYNE 31% v42,8M c1.20 f53,5M H1.3 S1.1 | znewcar1 | investorshangout | 12/06/2021 9:23:34 PM |
The follow-on order took awhile but it did fill. | jugs | investorshub | 11/24/2020 8:38:31 PM |
Picked up 300 $VYNE today at $1.64. Just | jugs | investorshub | 11/24/2020 7:49:26 PM |
We will fix that when it's time for | jugs | investorshub | 11/24/2020 4:58:44 PM |
Man we are going nowhere fast | pickspicks1 | investorshub | 11/24/2020 4:26:59 PM |
16 NOV 2020 $VYNE UPDATE | artfulife | investorshub | 11/18/2020 12:03:39 PM |
You might read the transcript that just came out. | jugs | investorshub | 11/13/2020 4:24:12 PM |
Is anything going on this one? No | pickspicks1 | investorshub | 11/13/2020 2:03:46 PM |
'OhhhAhhOhhAhhOhh AhhOhhAhhOhh!" (Swinging from $VYNE with my best | artfulife | investorshub | 10/29/2020 12:46:23 AM |
If you apply it tropically you can climb | jugs | investorshub | 10/29/2020 12:37:24 AM |
At least with $VYNE, you can apply it | artfulife | investorshub | 10/29/2020 12:16:15 AM |
Actually $VYNE is working on a cure for | jugs | investorshub | 10/28/2020 8:15:58 PM |
LOl Now why didnt I catch that | pickspicks1 | investorshub | 10/28/2020 6:20:50 PM |
R U saying you crap in your head? Wow! | jugs | investorshub | 10/28/2020 5:37:57 PM |
Sell at $2 buy back at 1.60! | pickspicks1 | investorshub | 10/28/2020 4:43:49 PM |
How nice!---Seeing shares trade at $2.01 and above | jugs | investorshub | 10/16/2020 2:53:46 PM |
$VYNE Director LePore Adopts 10b5-1 Purchasing Plan | Billr05 | investorshub | 10/13/2020 12:07:34 PM |
For the record, $VYNE gained 26 cents this | jugs | investorshub | 10/10/2020 2:49:36 PM |
Yeah, I can live with that! | artfulife | investorshub | 10/07/2020 11:59:45 PM |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage ...
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q...